A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
← catalyst calendarNCT06994897 · readout in 476 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
92estimated
Sites
1
Country
Belgium
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-13 | actual | When the study began enrolling |
| Primary completion | 2027-12-08 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-08 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: PF-07985631
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE)
measured Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)
Number of Participants With Vital Signs Values Meeting Categorical Summarization Criteria
measured Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)
Number of Participants With Notable Electrocardiogram (ECG) Values
measured Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)
Number of Participants With Clinically Significant Abnormal Laboratory Parameters
measured Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed